Registration partneringONE Program & Speakers



Ronen Shemesh, Dr., PhD

Sep 15, 11:10|Profarma Hall

FertiProt: Cannabinoid Receptors and the Cannabinoid System as Targets for Fertility Enhancement and an Alternative for Assisted Reproduction Treatment

Portfolio Manager at Quark Biopharmaceuticals

Holds a PhD in Genetics and Molecular Biology from the Hebrew University of Jerusalem. He has over 18 years of experience in the bio-med industry most of them in drug discovery, drug development and Genomics/Proteomics research and development. Ronen has published several top tier publications, and in an inventor of several patents on novel mechanisms and new insights in genomic, proteomic and molecular processes leading to several new discoveries and new biologic drugs. He has led a few projects of New Biological Entities discoveries, using machine learning, bioinformatics and computerized methods, as well as vast experience and knowledge in wet analysis and lab methods.
Currently, Ronen hold the position of “Portfolio Manager” at Quark Biopharmaceuticals (QBI), where he manages new developments and portfolio selection and modification. Until recently, Ronen was "Director, New Products Scientific Manager, GGR&D NTE" at the Global Generic R&D in TEVA Pharmaceuticals, where he took a critical part in building the company’s New Therapeutic Entities strategy, in which old, established drugs are being re-purposed and re-formulated using the 505(b)(2) regulatory pathway in order to make them more attractive for the market. Ronen is also a serial Entrepreneur; he has established several pre-seed projects and start-ups in the fields of Fertility, Drug discovery in various indications, Cancer immuno-therapy and Pharmacogenomics /Diagnostics. As such Ronen also has experience in Business development and management of complex organizations/teams.